Unravel the Complexities and Evaluate Potential Changes
June 13-14, 2018
- Washington, DC
CBI’s DIR Fees Forum provides an excellent opportunity to learn more about what DIR Fees are used for and how they currently impact pharmacy providers, health plans and PBMs. Don’t miss this unique opportunity to discuss such a timely, critical issue that is rapidly evolving.
CRITICAL TOPICS FOR DISCUSSION INCLUDE:
- Address how DIR Fees impact pharmacy players —
Retail, specialty & long-term care - Discuss the importance of the proposed bill,
S. 413/H.R. 1038 (“Improving Transparency and
Accuracy in Medicare Part D Drug Spending Act”) - Understand the concept of pay for performance and
how DIR Fees are adjusted - Evaluate how performance scores are affecting
specialty pharmacy and Medicare Part D patients - Identify the difficulties for pharmacies to assess true
reimbursement rates throughout the contract lifecycle - Discover how to proactively monitor DIR Fees
within your organization - Determine the financial impact of DIR fees on
340B contractual relationships
DIR Fees Forum
Unravel the Complexities and Evaluate Potential Changes
CBI’s DIR Fees Forum provides an excellent opportunity to learn more about what DIR Fees are used for and how they currently impact pharmacy providers, health plans and PBMs. Don’t miss this unique opportunity to discuss such a timely, critical issue that is rapidly evolving.
CRITICAL TOPICS FOR DISCUSSION INCLUDE:
- Address how DIR Fees impact pharmacy players —
Retail, specialty & long-term care - Discuss the importance of the proposed bill,
S. 413/H.R. 1038 (“Improving Transparency and
Accuracy in Medicare Part D Drug Spending Act”) - Understand the concept of pay for performance and
how DIR Fees are adjusted - Evaluate how performance scores are affecting
specialty pharmacy and Medicare Part D patients - Identify the difficulties for pharmacies to assess true
reimbursement rates throughout the contract lifecycle - Discover how to proactively monitor DIR Fees
within your organization - Determine the financial impact of DIR fees on
340B contractual relationships
